Kevin Zorn, MD, FRCSC, FACS, presented “Office BPH: 2024 Updates and Where Are We Going?” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 18, 2024, in San Diego, California.
>
How to cite: Zorn, Kevin. “Office BPH: 2024 Updates and Where Are We Going?.” October, 2024. Accessed Sep 2025. https://grandroundsinurology.com/office-bph-2024-updates-and-where-are-we-going/
Office BPH: 2024 Updates and Where Are We Going? – Summary
Kevin Zorn, MD, FRCSC, FACS, explores the evolving approaches to treating benign prostatic hyperplasia (BPH), emphasizing the need for early intervention and office-based procedures.
In this 15-minute presentation, Dr. Zorn addresses the growing global population of men requiring treatment, highlighting the increasing demand for efficient, minimally invasive solutions. He reviews the progression of technologies, including UroLift, Rezūm, and newer systems like OptilumeⓇ, which offer quick recovery, durability, and adaptability to patient needs.
Dr. Zorn underscores the importance of understanding prostatic architecture to tailor treatments. He discusses the evolution and reproducibility of stent-based technologies, comparing them to individualized techniques like UroLift. He highlights the critical role of imaging and anatomical assessment in refining procedural precision and selecting the best therapeutic approach for each patient.
Dr. Zorn advocates for advancements in local anesthesia techniques, enabling more procedures in office settings with improved patient comfort. By integrating these technological and procedural advancements, he envisions a future of personalized, effective, and accessible BPH care that maximizes outcomes while addressing the rising clinical demand.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Kevin C. Zorn, MD, FACS, FRCSC, is the founder of the BPH Canada Prostate Institute, a personalized, private, prostate solution center founded in 2023 to offer all approved BPH therapies to Canadian men, and director of Robotic & MIS BPH Prostate Surgery, Mont-Royal Surgical Center. Dr. Zorn is a former associate professor of urology at the University of Montreal (CHUM) and the University of Chicago, sub-specializing in robotic surgery and benign prostatic hyperplasia (BPH) surgical care.
Dr. Zorn attended McGill University for his pre-med program, his medical degree, and his residency in urological surgery. He became a fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC) in 2005. Dr. Zorn also completed a two-year fellowship in oncology and endourology at the University of Chicago. In 2007, he became American Board of Urology certified in urology and a fellow of the American College of Surgeons.
Research and innovation have been the hallmarks of Dr. Zorn’s career. Among his many firsts, he was the first in Canada and Québec to use many new BPH technologies, including Greenlight XPS, Rezum, iTind, Optilume, Aquablation and Zenflow. He has also been the first in Canada to introduce cutting-edge technologies including the Clarius and ButterflyIQ point-of care ultrasound (POCUS), as well as disposable AMBU4 cystoscopes for faster patient care and greater safety. He is among the first physicians globally to be named as a Center of Excellence for Rezum and Greenlight vaporization and VIT (vapor incision technique). He is an international speaker and surgical trainer for these techniques.
Dr. Zorn is the senior author of the Male lower urinary tract symptoms (LUTS)/BPH guidelines for the 2018 and 2022 Canadian Urological Association (CUA) and consulted on the American Urological Association BPH guidelines. He has also helped create national online programs in robotic prostate cancer care and rehabilitation as well as the CUA BPH patient decision-aid tool. Dr. Zorn has authored 400 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care. With such accolades, Dr. Zorn has become a sought-afterspeaker, teacher and researcher. He has traveled to lecture, teach, and proctor surgery around the world, and is intimately involved with the development of several pioneering BPH technologies. In 2024, Dr. Zorn retired from his position at the University of Montreal to dedicate his full clinical practice to BPH Canada.
